Sirtris Pharmaceuticals, acquired by GlaxoSmithKline, is focused on discovering and developing proprietary, small molecule drugs with the potential to treat diseases associated with aging, such as chronic disorders involving metabolic and inflammatory dysfunction and neurodegeneration.

The company's research focus is on modulating the sirtuins, a class of enzymes demonstrated to be involved in multiple diseases associated with advancing age.